Bayer's Consumer Health Struggles Continue In Q1, But The Firm Insists It's On The Right Track
Executive Summary
Bayer Consumer Health's sales declined at a single-digit rate in the first quarter of 2019, as the business continued to battle challenges in Europe and the US. Undeterred by this slow start to the year, the German firm says Consumer Health's performance will begin to turnaround in the coming months.
You may also be interested in...
Bayer Hopes Consumer Health Woes Are In Rear View Mirror As Business Returns To Growth
Bayer is starting to see green shoots of recovery after a prolonged period of declining sales and earnings at its Consumer Health business. Turnover improved by 2% in the second quarter, driven by gains in Europe and Latin America.
Q2 Consumer Health Earnings Preview: GSK And Bayer
GSK is looking to ramp up growth and focus its portfolio as its consumer health JV with Pfizer edges ever closer to completion. Meanwhile, Bayer is hoping to see the green shoots of recovery in Q2 with its Consumer Health turnaround plan now in full swing.
Bayer Pares Dr. Scholl's In Latest Step Toward Core Consumer Portfolio
Bayer follows through on plans to divest Dr. Scholl’s after selling Coppertone business in May to focus on consumer lines such as Aleve oral analgesics, Claritin allergy treatments and Bayer Aspirin. Private equity firm Yellow Wood Partners creating stand-alone company to operate Dr. Scholl's.